Nanotecton
Witryna24 sty 2014 · PICN is a novel formulation of Paclitaxel using SPARC’s proprietary Nanotecton platform technology and is a Cremophor and Albumin-free formulation. It offers the convenience of a quick and easy one-step dilution and infusion preparation for healthcare professionals. PICN can be administered in a short 30 minute infusion and … WitrynaNANOTECTON Sun Pharma Advanced Research Company Limited. USPTO Trademarks › Sun Pharma Advanced Research Company Limited › Nanotecton Application #86500456. Trademark Registered: 2024-10-09. Trademark Application Details. Status Refresh. 700. Live/Registered. REGISTERED. Research: OneLook …
Nanotecton
Did you know?
Witryna3 mar 2016 · Paclitaxel is widely used in the treatment of patients with metastatic breast cancer (MBC). Formulations of paclitaxel contain surfactants and solvents or albumin derived from human blood. The use of co-solvents such as polyoxyethylated castor oil is thought to contribute to toxicity profile and hypersensitivity reactions as well as … Witryna20 maj 2013 · 3039 Background: PICN is a novel solvent and protein-free 100-110 nm particle formulation of paclitaxel stabilized with polymer and lipid using Nanotecton Technology. Paclitaxel has shown superior safety and efficacy profile when administered on a weekly schedule. We studied safety, tolerability, and pharmacokinetics (PK) of …
Witryna20 maj 2014 · Background: PICN is a novel, solvent- and protein-free, 100-110 nm particle formulation of paclitaxel stabilized with polymer and lipids using … Witryna7 lip 2015 · Based on SUN PHARMA ADVANCED RESEARCH COMPANY, the NANOTECTON trademark is used in the following business: Development of new …
http://www.pharmabiz.com/NewsDetails.aspx?aid=79986&sid=2 Witryna7 sty 2024 · The USPTO has given the NANOTECTON trademark a serial number of 85744325. The federal status of this trademark filing is REGISTERED as of Tuesday, …
WitrynaNeoton - proszek i rozpuszczalnik do sporządzania roztworu do infuzji Substancja wysokoenergetyczna, dostarczająca energii do resyntezy ATP w mięśniach …
WitrynaOur CAR-T reagents help our customers to make better, more effective cell therapies, faster. Cancer cell therapies are the cancer treatment of the future. The foundation of … chase millions or passionWitryna24 lut 2024 · Taclantis is a novel formulation of paclitaxel developed with SPARC's proprietary Nanotecton technology. Paclitaxel is one of the most widely used cytotoxic agent and is approved for the treatment of breast cancer, ovarian cancer, non small cell lung cancer and pancreatic cancer. In its Appeal Denied letter, the OND requested … cushe mellow shoesWitrynaPICN is a novel Cremaphor-free composite of paclitaxel nano-particles stabilized with polymer and lipid using Nanotecton Technology and the MTD of PICN alone was previously determined as 0.2557. 2557 Background: PICN is a novel Cremaphor-free composite of paclitaxel nano-particles stabilized with polymer and lipid using … chase mills trackwrestlingWitrynaThe USPTO has given the NANOTECTON trademark a serial number of 86496920. The federal status of this trademark filing is ABANDONED - EXPRESS as of Tuesday, … chase military travel cardWitrynaSPARC’s proprietary Nanotecton TM technology is based on forming a complex of drug with polymer and lipids in an optimum ratio to achieve a ‘packing’ parameter that allows self-assembly of the composition into nanoparticles of 50-150 nm in … cushe men\\u0027s fashion sneakerWitrynaNANOTECTON Sun Pharma Advanced Research Company Ltd. USPTO Trademarks › Sun Pharma Advanced Research Company Ltd. › Nanotecton Application … cushe mens slip-onsWitryna12 lut 2024 · SPARC had informed the bourses on 1 July 2024 that USFDA has accepted the company's NDA for Taclantis, a novel formulation of Paclitaxel developed with … cushe mens oxfords